Rapid Onset Liquid Midazolam Composition for Buccal Administration

Abstract

This application discloses liquid compositions for administration to a patient comprising midazolam and a pharmaceutically acceptable carrier, wherein the pH of the composition is about 6 or higher, the composition comprises less than about 200 mg/ml cyclodextrin, and at least about 50% of the midazolam is present in solution. Uses of these compositions are also disclosed.

1 . A liquid composition for administration to a patient comprising midazolam and a pharmaceutically acceptable carrier, wherein the pH of the composition is 6 or higher, the viscosity of the composition is 200 to 400 CP, the composition comprises less than 200 mg/ml cyclodextrin, and at least 50% of the midazolam is present in solution. 
     
     
         2 . The liquid composition of  claim 1 , wherein the composition is for administration via at least one of the buccal, nasal, rectal and/or sub-lingual routes. 
     
     
         3 . The liquid composition of  claim 1 , wherein the pH of the composition is 7 or higher. 
     
     
         4 . The liquid composition of  claim 1 , wherein the pH of the composition is 8 or higher. 
     
     
         5 . The liquid composition of  claim 1 , wherein the pH of the composition is 8 to 11. 
     
     
         6 . The liquid composition of  claim 1 , wherein the pH of the composition is 8 to 10.5 
     
     
         7 . The liquid composition of  claim 1 , wherein the pH of the composition is 8 to 10. 
     
     
         8 . The liquid composition of  claim 1 , wherein at least 90% of the midazolam is present in solution. 
     
     
         9 . The liquid composition of  claim 1 , wherein at least 98% of the midazolam is present in solution. 
     
     
         10 . The composition of  claim 1 , wherein the concentration of midazolam is 5 mg/ml to 20 mg/ml. 
     
     
         11 . The composition of  claim 1 , wherein the concentration of midazolam is 6 mg/ml to 15 mg/mi. 
     
     
         12 . The composition of  claim 1 , wherein the concentration of midazolam is 7.5 mg/ml to 12.5 mg/mi. 
     
     
         13 . The composition of  claim 1 , wherein the viscosity of the composition is 250 CP to 350 CP. 
     
     
         14 . The composition of  claim 1 , wherein the viscosity of the composition is 270 CP to 330 CP. 
     
     
         15 . The composition of  claim 1 , wherein the composition further comprises a viscosity enhancing component. 
     
     
         16 . The composition of  claim 1 , wherein the composition comprises 50 mg/ml or less of cyclodextrin. 
     
     
         17 . The composition of  claim 1 , wherein the composition is free of cyclodextrin. 
     
     
         18 . The composition of  claim 1 , wherein the composition further comprises a buffer. 
     
     
         19 . The composition of  claim 18 , wherein the buffer is a phosphate buffer, a glycine/NaOH buffer or a carbonate or bicarbonate buffer or a mixture thereof. 
     
     
         20 . The composition of  claim 1 , wherein the composition additionally comprises at least one of a sweetener, a flavour enhancer, a preservative and/or an antifungal agent. 
     
     
         21 . The composition of  claim 1 , wherein the carrier comprises at least one of water, ethanol, glycerine, glycerol, polyethylene glycol, propylene glycol or mixtures thereof. 
     
     
         22 . The composition of  claim 1 , further comprising an additional therapeutic agent. 
     
     
         23 - 33 . (canceled) 
     
     
         34 . A method of treating an epileptic seizure and/or inducing a degree of anaesthesia in a patient, comprising administering a liquid composition to a patient, the composition comprising midazolam and a pharmaceutically acceptable carrier, wherein the pH of the composition is 6 or higher, the viscosity of the composition is 200 to 400 CP, the composition comprises less than 200 mg/ml cyclodextrin, and at least 50% of the midazolam is present in solution. 
     
     
         35 . The method of  claim 34 , wherein the patient is 14 years of age or under. 
     
     
         36 . The method of  claim 34 , wherein the patient is simultaneously or sequentially administered an additional therapeutic agent. 
     
     
         37 . The method of  claim 36 , wherein the composition comprises the additional therapeutic agent. 
     
     
         38 . The method of  claim 37 , wherein the additional therapeutic agent is selected from the group consisting of corticosteroids, cytotoxics, antibiotics, immunosupressants, nonsteroidal antiinflammatory drug, narcotic analgesics, local anaesthetics, NMDA antagonists, neuroleptics, anticonvulsants, antispasmodics, antiemetics, antidepressants and muscle relaxants.